During the 12 week trial that included 83 term infants, 58 were formula-fed while the rest were breast-fed.
The formula fed infants were either assigned to a control group receiving formula using standard vegetable oil mix or a study group receiving formula with InFat, who have shown higher bone parameters.
Enzymotec Infant Nutrition research and development director Yael Lifshitz said the trial indicates that InFat benefits bone strength parameters.
"Bone speed of sound of the newborns fed the formula with InFat was significantly higher than that of newborns fed the control formula, and comparable to that of breast-fed newborns," Lifshitz added.
Advanced Lipids CEO Tzafra Cohen said, "This trial marks an important milestone in our clinical development program, positioning InFat as a premium fat blend for infant formulas."
Advanced Lipids is a joint venture between AAK and Enzymotec for the sales and marketing of InFat.
InFat is a fat blend (beta-palmitate structured lipids) for infant formula with a high percentage of palmitic acid in its sn-2 position.